Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

• Main Authors: Prakash K. Bhuyan (Author), Michael Dallas (Author), Kim Kraynyak (Author), Timothy Herring (Author), Matthew Morrow (Author), Jean Boyer (Author), Susan Duff (Author), Joseph Kim (Author), David B. Weiner (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up to 1.5 y followin...